Table 1. Patient and Disease Characteristics.
| Characteristics | Group 1 (n = 41) | Group 2 (n = 31) |
|---|---|---|
| Male/female | 22/19 | 17/14 |
| Age, median (range) years | 58 (25 - 75) | 59 (43 - 75) |
| Durie-Salmon/ ISS | ||
| I A/I | 2/19 | 3/11 |
| II A/I | 12/11 | 9/11 |
| III A/IIIB/III | 23/4/5 | 13/6/5 |
| B2M, mg/L, median (range) | 2.27 (0.84 - 14.1) | 2.6 (1.45 - 69.6) |
| Median follow-up (range), months | 36 (6 - 84) | 31 (11 - 73) |
| Lines of therapy before HCT | ||
| 1 | 28 | 20 |
| 2 | 9 | 7 |
| 3 | 4 | 4 |
| Conditioning for first autologous HCT | ||
| Melphalan | 32 | 18 |
| Busulfan/cyclophosphamide +/- etoposide | 9 | 13 |
| Cytogenetics/FISH | ||
| Normal | 25 | 24 |
| Complex/hyperdiploid and del 13 by cytogenetics | 4 | 1 |
| Hyperdiploid without deletions | 6 | 3 |
| FISH + chromosomes 13,14, or 17 | 3 | 3 |
| Del Y | 2 | 1 |
| Time to first auto HCT: median (range) months | 7 (3 - 60) | 7 (3 - 39) |
| Tandem autologous/autologous HCT | 5 | 4 |
| Tandem autologous/allogeneic HCT | 5 | 6 |
| Salvage autologous/autologous HCT | 4 | 1 |
| Salvage autologous/allogeneic HCT | 6 | 2 |
| Maintenance lenalidomide | 4 | 1 |
| Maintenance thalidomide/interferon | 5 | 6 |
Abbreviations: HCT: hematopoietic cell transplant; FISH: fluorescence in situ hybridization; ISS: international staging system; B2M: beta 2 microglobulin; WBCT: whole body computerized tomography; CSS: conventional skeletal survey; Group 1: Patients who had more myelomatous bone disease detected on WBCT than CSS; Group 2: Patients without any differences between CSS and WBCT in the detection of myelomatous bone disease.